Buccal tablets
The multi-layered structure of the lozenges solves the problem of limited functionality in existing lozenges, enabling flexible release of active ingredients and flavorings to meet diverse user needs and enhance the user experience.
Patent Information
- Application Number
- CN202521585117.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Utility models(China)
- Current Assignee / Owner
- Filing Date
- 2025-07-28
- Publication Date
- 2026-11-03
- Estimated Expiration
- 2035-07-28
AI Technical Summary
Existing lozenges have limited functionality and cannot meet the diverse needs of users.
A multi-layered lozenge was designed, comprising a first support layer, a functional layer, a flavoring layer, and a second support layer. By designing different water permeability and porosity, it is used to release active substances and flavoring agents, respectively. An isolation layer can be optionally added to control the migration of substances between layers.
This multi-functional lozenge provides support and protection, while also allowing for adjustable release rates of active ingredients and flavorings to improve the user experience.
Smart Images
Figure CN224924572U_ABST
Abstract
Description
Technical Field
[0001] This application relates to the field of oral lozenges, and in particular to an oral lozenge. Background Technology
[0002] Oral products, such as nicotine lozenges, are products containing the active ingredient nicotine (nicotine or its derivatives). They are usually placed in the mouth in the form of powder, tablets, or sachets, where they dissolve and release the active ingredient nicotine, which is then absorbed through the oral mucosa, thereby relieving nicotine withdrawal symptoms when quitting smoking.
[0003] Lozenges are tablet or film-like products, usually made of soluble materials, containing a certain amount of functional substances. When used, they are placed in the mouth and come into contact with saliva, causing the lozenge to disintegrate or swell and release the functional substances.
[0004] However, current lozenges are usually single-layered with limited functionality, which cannot meet users' needs. Utility Model Content
[0005] This application provides a lozenge to address the problem that current lozenges have limited functionality and cannot meet user needs, and provides a lozenge with multiple functions to better meet user requirements.
[0006] This application discloses a lozenge, which sequentially includes a first support layer, a functional layer, a flavoring layer, and a second support layer. The functional layer is configured to contain an active substance, and the flavoring layer is configured to contain a flavoring agent.
[0007] In one implementation of this application, the lozenge further includes an isolation layer disposed between the functional layer and the flavoring layer.
[0008] In one implementation of this application, the functional layer includes a first functional layer and a second functional layer, and the lozenge further includes an isolation layer disposed between the first functional layer and the second functional layer.
[0009] In one implementation of this application, the first support layer, the isolation layer, and the second support layer are fixed to each other.
[0010] In one implementation of this application, the first support layer, the diaphragm, and the second support layer are fixed to each other by a stitching structure or a pressing structure.
[0011] In one implementation of this application, the first support layer and the second support layer are water-permeable, and the water permeability of the first support layer is different from that of the second support layer.
[0012] In one implementation of this application, the porosity of the first support layer and the porosity of the second support layer are different.
[0013] In one implementation of this application, the first support layer and the second support layer are porous structures, wherein the oral tablet satisfies at least one of (I) to (V): (I) the first support layer is provided with at least one of microporous structure and macroporous structure; (II) the second support layer is provided with at least one of microporous structure and macroporous structure; (III) the first support layer and / or the second support layer are temperature-sensitive support layers, which are used to adjust their water permeability based on temperature changes; (IV) the porosity of the first support layer and / or the second support layer is 5% to 30%; (V) the pore size of the first support layer and / or the second support layer is 5 μm to 50 μm.
[0014] In one implementation of this application, the first support layer and the second support layer together form a bag structure, the bag structure having a receiving space, and the functional layer and the flavoring layer are received in the receiving space.
[0015] In one implementation of this application, the mouthpiece further includes a gripping portion connected to the first support layer and / or the second support layer, the gripping portion being used to grip the mouthpiece.
[0016] Due to the adoption of the above technical solutions, the beneficial effects of this application are as follows:
[0017] The lozenge of this application includes a multi-layer structure, with a first support layer and a second support layer providing support and protection; a functional layer and a flavoring layer providing active substances and flavoring agents to users respectively, in order to meet more usage scenarios and more personalized usage needs of users. Attached Figure Description
[0018] Figure 1 A schematic diagram of the structure of a lozenge according to a specific embodiment of this application is shown.
[0019] Figure 2 A schematic diagram of the structure of a lozenge according to another specific embodiment of this application is shown.
[0020] Figure 3 A schematic diagram of the structure of a lozenge according to another specific embodiment of this application is shown. Detailed Implementation
[0021] The present application will now be described in further detail with reference to specific embodiments and accompanying drawings. In the following embodiments, many details are described to facilitate a better understanding of the present application. However, those skilled in the art will readily recognize that some features may be omitted in different situations, or may be replaced by other materials or methods. In some cases, certain operations related to the present application are not shown or described in the specification. This is to avoid obscuring the core parts of the present application with excessive description. For those skilled in the art, detailed description of these related operations is not necessary; the relevant operations can be fully understood based on the description in the specification and general technical knowledge in the art.
[0022] Furthermore, the features, operations, or characteristics described in the specification can be combined in any suitable manner to form various embodiments. At the same time, the steps or actions in the method description can be rearranged or adjusted in a manner obvious to those skilled in the art. Therefore, the various orders in the specification and drawings are only for the clear description of a particular embodiment and do not imply a necessary order, unless otherwise stated that a particular order must be followed.
[0023] Figure 1 A schematic diagram of the structure of a lozenge 100 according to a specific embodiment of this application is shown. It should be noted that in the schematic diagram of the structure of the lozenge 100 of this application, the layers are shown separately for ease of displaying the structure of different layers. In actual case, the layers are in contact with each other.
[0024] In one specific embodiment, the lozenge 100 has a multi-layered structure.
[0025] In one specific embodiment, the lozenge 100 may include a support layer. The support layer may be water-insoluble. The support layer may have a porous structure. The support layer may be water-permeable. The support layer may have pores to allow saliva to pass through it. It should be noted that the support layer serves a supporting and protective function, as well as allowing saliva to pass through and enter other membrane layers. Furthermore, after use, removing the support layer can remove undissolved membrane debris, reducing the foreign body sensation caused by residue and improving the user experience.
[0026] In one specific embodiment, the support layer may include at least one of thermoplastic resin porous membrane, natural fiber nonwoven fabric, synthetic fiber nonwoven fabric, and woven fabric. It should be noted that natural fiber nonwoven fabric, synthetic fiber nonwoven fabric, and woven fabric have good hydrophilicity, which enables the support layer to have good hydrophilicity, facilitating the passage of saliva through the support layer into other internal structural layers.
[0027] In one specific embodiment, the thermoplastic resin may include, but is not limited to: PP (polypropylene), PET (polyethylene terephthalate), PA (polyamide, also known as nylon), and PLA (polylactic acid).
[0028] In one specific embodiment, the support layer can be a porous thermoplastic resin membrane. For example, the support layer can be a porous polypropylene membrane.
[0029] In one specific embodiment, the pore size of the support layer can be 5μm to 50μm. For example, the pore size of the support layer can be 5μm, 10μm, 25μm, 40μm, or 50μm.
[0030] In one specific embodiment, the porosity of the support layer can be 5% to 30%. For example, the porosity of the support layer can be 5%, 10%, 15%, 20%, 25%, or 30%.
[0031] In one specific embodiment, the number of support layers can be multiple.
[0032] In one specific embodiment, at least two support layers may be located on two surfaces of the mouthpiece 100, respectively. For example... Figure 1 As shown, in one specific embodiment, the support layer may include a first support layer 10 and a second support layer 50. In some embodiments, the first support layer 10 and the second support layer 50 have the same water permeability. In some embodiments, both the first support layer 10 and the second support layer 50 are water permeable, but the water permeability of the first support layer 10 is different from that of the second support layer 50. Therefore, the release rate of active substances and flavorings can be adjusted by varying the water permeability to better meet user needs.
[0033] In one specific embodiment, the support layer is a temperature-sensitive support layer. The temperature-sensitive support layer is used to adjust its water permeability based on temperature changes. A temperature-sensitive support layer may refer to a support layer containing a temperature-sensitive additive that adjusts the water permeability of the support layer based on temperature changes. For example, the temperature-sensitive additive can adjust the water permeability of the support layer by increasing the porosity of the support layer when the temperature rises.
[0034] In one specific embodiment, the temperature-sensitive additive can undergo morphological changes upon heating or cooling. When the temperature rises, the temperature-sensitive additive expands due to heat, increasing the pores and thus the porosity. Conversely, when cooled, the shrinkage or precipitation of the temperature-sensitive additive may lead to a redistribution of the pores, reducing the porosity. In this case, the lozenge 100 has the function of slow release of the active ingredients (including active substances and flavoring agents) at low temperatures, and accelerated release of the active ingredients when heated in the oral cavity.
[0035] In one specific embodiment, the temperature-sensitive additive may be poly(N-isopropylacrylamide) (PNIPAM).
[0036] In one specific embodiment, the temperature-sensitive additive may adhere to the pores of the support layer.
[0037] In one specific embodiment, the temperature-sensitive additive can be attached to the pores of the support layer by immersing the support layer in an impregnation solution containing a temperature-sensitive additive.
[0038] In one specific embodiment, the first support layer 10 may be a temperature-sensitive support layer.
[0039] In one specific embodiment, the second support layer 50 may be a temperature-sensitive support layer.
[0040] In one specific embodiment, the porosity of the first support layer 10 and the second support layer 50 can be the same.
[0041] In one specific embodiment, the porosities of the first support layer 10 and the second support layer 50 may be different. For example, the porosity of the second support layer 50 may be greater than that of the first support layer 10. This allows moisture to enter the flavoring layer 40 (described in detail below) more quickly, and also allows the flavoring agents in the flavoring layer 40 to be released more quickly, masking the off-flavors of the active substances and improving the taste. In some embodiments, the release rate of the active substances in the functional layer 20 (described in detail below) is controlled by the porosity of the first support layer. Alternatively, the porosity of the second support layer 50 may be less than that of the first support layer 10. This allows the active substances to have a relatively faster release rate to meet the user's needs.
[0042] In one specific embodiment, the thickness of the first support layer 10 can be 0.1 mm to 0.2 mm. For example, the thickness of the first support layer 10 can be 0.1 mm, 0.13 mm, 0.15 mm, 0.17 mm or 0.2 mm.
[0043] In one specific embodiment, the thickness of the second support layer 50 can be 0.1 mm to 0.2 mm. For example, the thickness of the second support layer 50 can be 0.1 mm, 0.13 mm, 0.15 mm, 0.17 mm, or 0.2 mm.
[0044] In one specific embodiment, the lozenge 100 may include a functional layer 20. The functional layer 20 may include an active substance.
[0045] In one specific embodiment, the active substance may include at least one of nicotine and nicotine derivatives, used to provide a sense of satisfaction.
[0046] In one specific embodiment, nicotine may include natural nicotine and synthetic nicotine. Nicotine derivatives may include one or more of the following: nicotine salts, nicotine in a matrix such as a glycobase or an organometallic complex, nicotine-resin combinations, nicotine inclusion complexes, and non-covalently bound nicotine. Non-covalently bound nicotine includes nicotine lactate, nicotine malate, nicotine salicylate, nicotine cyclodextrin-encapsulated complexes, nicotine hydrochloride, nicotine dihydrochloride, nicotine tartrate, nicotine tartrate dihydrate, nicotine sulfate, nicotine zinc chloride, and nicotine benzoate. Nicotine derivatives also include nicotine containing substituents, such as one or more mixtures of hexamethylnicotine, hexamethylnicotine lactate, hexamethylnicotine malate, hexamethylnicotine salicylate, hexamethylnicotine cyclodextrin encapsulated complex, hexamethylnicotine hydrochloride, hexamethylnicotine dihydrochloride, hexamethylnicotine tartrate, hexamethylnicotine tartrate dihydrate, hexamethylnicotine sulfate, hexamethylnicotine zinc chloride, and hexamethylnicotine benzoate.
[0047] In one specific embodiment, the active substance may also be selected from other substances with medical or other specific uses, such as vitamins, capsaicin, caffeine, etc., to meet the needs of different users.
[0048] In one specific embodiment, the active substance may also be selected from other alkaloids or amino acids. For example, alkaloids such as tobacco, coffee, and tea.
[0049] In one embodiment, the functional layer 20 may be located in the inner layer of the lozenge 100. In another embodiment, the support layer may be located in the outer layer, and the functional layer 20 may be located in the inner layer, thereby protecting the functional layer through the support layer.
[0050] like Figure 1 As shown, in one specific embodiment, the lozenge 100 may include a flavoring layer 40. The flavoring layer 40 may include a flavoring agent. The flavoring agent may include at least one of a sweetener, a flavoring agent, and a cooling agent.
[0051] In one embodiment, functional layer 20 may contain active substances but not flavoring agents. Flavoring layer 40 may contain flavoring agents but not active substances. Thus, active substances and flavoring agents can be loaded in different layers, reducing intermolecular competitive adsorption or interference between them. In some examples, functional layer 20 may also contain flavoring agents, but the content of flavoring agents in functional layer 20 is lower than the content of flavoring agents in flavoring layer 40. In some embodiments, functional layer 20 may contain sweeteners and cooling agents but not flavoring agents; the flavoring layer includes flavoring agents.
[0052] In one specific embodiment, the sweetener may include at least one selected from xylitol, sorbitol, mannitol, iodine, lactitol, maltitol, isomaltitol, hydrogenated starch hydrolysate, erythritol, maltodextrin, aspartame, acesulfame potassium, sodium saccharin, sucralose, neotame, cyclamate, alitane, steviol glycosides, arabinitol, and monk fruit sweetener. The sweetener may also be selected from other edible-grade substances, which will not be elaborated upon herein.
[0053] In one specific embodiment, the flavoring agent may include at least one of fragrances, natural essential oils, and natural extracts. The fragrance is an edible fragrance, which may include at least one of bergamot fragrance, eucalyptus fragrance, citrus fragrance, lemon fragrance, peppermint fragrance, peppermint fragrance, menthol, licorice fragrance, wintergreen fragrance, tobacco fragrance, coffee fragrance, vanilla fragrance, lime fragrance, apple fragrance, peach fragrance, mango fragrance, cherry fragrance, blueberry fragrance, strawberry fragrance, cola fragrance, cinnamon fragrance, vanilla fragrance, and watermelon fragrance. The flavoring agent may also be other types of edible fragrances, which will not be described in detail here.
[0054] In one specific embodiment, the cooling agent may include at least one of menthol, menthol derivatives, WS-3, and WS-23.
[0055] Figure 2 A schematic diagram of the structure of a lozenge 100 according to another specific embodiment of this application is shown.
[0056] In one specific embodiment, the lozenge 100 may include an isolation layer 30.
[0057] In one specific embodiment, the isolation layer 30 can be a hydrophobic membrane or a water-repellent membrane. The isolation layer 30 can be impermeable to water. The isolation layer 30 is hydrophobic, capable of blocking, controlling, or delaying the passage of moisture.
[0058] In one specific embodiment, the isolation layer 30 can separate the functional layer 20 and the flavoring layer 40. Specifically, the functional layer 20 can be located between the first support layer 10 and the isolation layer 30. The flavoring layer 40 can be located between the isolation layer 30 and the second support layer 50. Thus, the isolation layer 30 can separate the functional layer 20 and the flavoring layer 40, reducing molecular migration between the active substances and flavoring agents in the functional layer 20 and the flavoring layer 40, thereby reducing the impact on taste.
[0059] In one specific embodiment, the lozenge 100 may sequentially include a first support layer 10, a functional layer 20, an isolation layer 30, a flavoring layer 40, and a second support layer 50.
[0060] In one specific embodiment, the first support layer 10 and the second support layer 50 can be fixed to each other. For example, they can be fixed to each other by a stitching structure or a pressing structure.
[0061] In one specific embodiment, the first support layer 10, the isolation layer 30, and the second support layer 50 can be fixed to each other. For example, they can be fixed to each other by a stitching structure or a pressing structure.
[0062] In one specific embodiment, the first support layer 10, the functional layer 20, the isolation layer 30, the flavoring layer 40, and the second support layer 50 can be fixed to each other. For example, they can be fixed to each other by a stitching structure or a pressing structure.
[0063] In one specific embodiment, the first support layer 10 and the second support layer 50 can together form a bag structure. The bag structure has an accommodating space in which the functional layer 20 and the flavoring layer 40 can be accommodated. The bag structure can be a fully enclosed bag structure or a semi-enclosed bag structure. This allows the functional layer 20 and the flavoring layer 40 to be located within the bag structure, which helps to prevent fragments of the functional layer 20 or the flavoring layer 40 from entering the oral cavity and causing adhesion or local discomfort.
[0064] In one specific embodiment, the first support layer 10 and the second support layer 50 can together form a bag structure. The bag structure has an accommodating space in which the functional layer 20, the isolation layer 30, and the flavoring layer / 40 can be accommodated. The bag structure can be a fully enclosed bag structure or a semi-enclosed bag structure.
[0065] In one embodiment, the mouthpiece 100 may further include a gripping portion (not shown). The gripping portion may be connected to the first support layer 10 and / or the second support layer 50. The gripping portion may be strip-shaped, rod-shaped, etc. The gripping portion is used to grip the mouthpiece 100 to facilitate the user picking up the mouthpiece 100.
[0066] In one specific embodiment, the isolation layer 30 can be at least one of polytetrafluoroethylene film, polyethylene film, polyvinylidene fluoride film, polyurethane film, silicone rubber film, and silicone-coated fabric. It should be noted that the isolation layer 30 can block and regulate the entry of moisture from both layers of the lozenge 100 into the functional layer 20 or flavoring layer 40 simultaneously, which helps prevent the lozenge 100 from dissolving too quickly in the mouth. Furthermore, the hydrophobic film 30 can be used as a coating substrate to directly coat and form the functional layer 20 and flavoring layer 40 on its surface.
[0067] In one specific embodiment, the thickness of the isolation layer 30 can be 50 μm to 100 μm. For example, the thickness of the isolation layer 30 can be 50 μm, 75 μm, or 100 μm.
[0068] In one specific embodiment, the first support layer 10, the isolation layer 30, and the second support layer 50 can be fixedly connected to each other. Therefore, after using the lozenge 100, the first support layer 10, the isolation layer 30, and the second support layer 50 can be removed together, reducing the increased difficulty of removal caused by the layering or displacement of the first support layer 10, the isolation layer 30, and the second support layer 50.
[0069] In one specific embodiment, when the lozenge 100 is used, the first support layer 10 can be the side closer to the oral mucosa or lips, and the second support layer 50 can be the side closer to the gums or tongue. This allows the active substances in the functional layer 20 to be absorbed more readily into the body through the oral mucosa or lip mucosa, reducing the amount of active substances entering the mouth and stomach via saliva, thereby reducing stomach irritation. Furthermore, the flavoring agents in the flavoring layer 40 can enter the mouth through saliva, enhancing flavor, masking any unpleasant odors of the active substances, and improving the user experience.
[0070] In one specific embodiment, when the oral lozenge 100 is used, the second support layer 50 may be the side closer to the oral mucosa or lips, and the first support layer 10 may be the side closer to the gums or tongue.
[0071] In one specific embodiment, the functional layer 20 contains an active substance. The flavoring layer 40 contains a flavoring agent. During use, the moisture in saliva causes the functional layer 20 and the flavoring layer 40 to dissolve or swell, releasing the active substance or flavoring agent.
[0072] In one specific embodiment, the swelling rate of the flavoring layer 40 can be higher than that of the functional layer 20. For example, the flavoring layer 40 can be made to release the flavoring agent earlier and / or faster than the active substance in the functional layer 20 by using a film-forming agent material with a faster swelling rate; or the functional layer 20 can contain a sustained-release agent with better sustained-release effect or in greater quantity to slow down the release of the active substance in the functional layer 20. This can help enhance the flavor, mask the nicotine odor, and improve the user experience. For first-time users, this can increase acceptance. In other examples, the swelling rate of the flavoring layer 40 can also be lower than that of the functional layer 20 to give the lozenge 100 a more balanced taste.
[0073] In one specific embodiment, the release rate of the active substance in the flavoring layer 40 can be higher than the release rate of the active substance in the functional layer 20. This allows the lozenge 100 to release the flavoring agent more quickly, which helps enhance flavor, mask the nicotine odor, and improve the user experience. In other examples, the release rate of the active substance in the flavoring layer 40 can also be lower than the release rate of the active substance in the functional layer 20.
[0074] In one specific embodiment, the thickness of the functional layer 20 can be 50 μm to 200 μm. For example, the thickness of the functional layer 20 can be 50 μm, 100 μm, 150 μm or 200 μm.
[0075] In one specific embodiment, the thickness of the flavoring layer 40 can be from 50 μm to 1000 μm. For example, the thickness of the flavoring layer 40 can be 50 μm, 100 μm, 250 μm, 500 μm, 750 μm or 1000 μm.
[0076] Figure 3 A schematic diagram of the structure of a lozenge 100 according to another specific embodiment of this application is shown.
[0077] In one specific embodiment, the functional layer 20 may include a first functional layer 21 and a second functional layer 22. The first functional layer 21 and the second functional layer 22 contain active substances.
[0078] In one specific embodiment, the first functional layer 21 and the second functional layer 22 can be located on opposite sides of the isolation layer 30, respectively. Thus, the lozenge 100 has two functional layers, which is beneficial for meeting the needs of more usage scenarios and more users' personalized usage.
[0079] In one specific embodiment, the first functional layer 21 and the second functional layer 22 may be the same.
[0080] In one specific embodiment, the first functional layer 21 and the second functional layer 22 may be different. For example, the active substances contained in the first functional layer 21 and the second functional layer 22 may be different, or they may contain the same active substances but with different concentrations or other components (e.g., film-forming agents).
[0081] In one specific embodiment, the active substances in the first functional layer 21 and the second functional layer 22 can have different release rates. For example, the release rate of the active substance in the first functional layer 21 may be lower than that of the active substance in the second functional layer 22; or, the release rate of the active substance in the first functional layer 21 may be higher than that of the active substance in the second functional layer 22. It should be noted that most current lozenge products adopt a single functional layer design, resulting in a single release rate of the active substance. For example, for rapid release, the release rate is relatively fast, which cannot meet the needs of long-lasting release. By setting multiple functional layers 20, and having different release rates of the active ingredients in the multiple functional layers 20, it is beneficial to better meet user needs, such as balancing the dual needs of rapid release and sustained release.
[0082] In one specific embodiment, the release rate of the active substances in the first functional layer 21 and the second functional layer 22 can be controlled by at least one of the following: the water permeability of the first support layer 10 and / or the second support layer 50 (porosity of the first support layer 10 and / or the second support layer 50), the formulation in the first functional layer 21 and / or the second functional layer 22 (e.g., the amount of sustained-release agent, the use of different film-forming agents or different amounts of film-forming agents, etc.).
[0083] In one specific embodiment, the lozenge 100 may sequentially include a first support layer 10, a first functional layer 21, an isolation layer 30, a second functional layer 22, a flavoring layer 40, and a second support layer 50.
[0084] In one specific embodiment, the functional layer 20 may include a first film-forming agent.
[0085] In one specific embodiment, the flavoring layer 40 may include a second film-forming agent.
[0086] In one specific embodiment, the first film-forming agent may include at least one of hydroxypropyl methylcellulose (HPMC), polyvinyl alcohol, pullulan, gelatin, chitosan, polyvinylpyrrolidone, and sodium carboxymethyl cellulose.
[0087] In one specific embodiment, the second film-forming agent may include at least one of hydroxypropyl methylcellulose (HPMC), polyvinyl alcohol (PVA), pullulan, gelatin, chitosan, polyvinylpyrrolidone, and sodium carboxymethyl cellulose.
[0088] In one specific embodiment, the hydroxypropyl methylcellulose (HPMC) can be a low-viscosity hydroxypropyl methylcellulose (HPMC). For example, it can be at least one of HPMC E3, HPMC E4, and HPMC E5.
[0089] The above description, in conjunction with specific embodiments, provides a further detailed explanation of this application and should not be construed as limiting the specific implementation of this application to these descriptions. For those skilled in the art, various simple deductions or substitutions can be made without departing from the concept of this application, and all such modifications or substitutions should be considered within the scope of protection of this application.
Claims
1. A lozenge, characterized in that, It comprises, in sequence, a first support layer, a functional layer, a flavoring layer, and a second support layer, wherein the functional layer is configured to contain active substances and the flavoring layer is configured to contain flavoring agents.
2. The lozenge as described in claim 1, characterized in that, The lozenge also includes an isolation layer disposed between the functional layer and the flavoring layer.
3. The lozenge as described in claim 1, characterized in that, The functional layer includes a first functional layer and a second functional layer, and the lozenge further includes an isolation layer disposed between the first functional layer and the second functional layer.
4. The lozenge as described in claim 2 or 3, characterized in that, The first support layer, the isolation layer, and the second support layer are fixed to each other.
5. The lozenge as described in claim 4, characterized in that, The first support layer, the isolation layer, and the second support layer are fixed together by a stitching structure or a pressing structure.
6. The lozenge as described in claim 1, characterized in that, The first support layer and the second support layer are water-permeable, and the water permeability of the first support layer is different from that of the second support layer.
7. The lozenge as described in claim 6, characterized in that, The porosity of the first support layer is different from that of the second support layer.
8. The lozenge as described in claim 1, characterized in that, The first support layer and the second support layer are porous structures, wherein the oral tablet satisfies at least one of (I) to (V): (I) The first support layer is provided with at least one of microporous structure and macroporous structure; (II) The second support layer is provided with at least one of microporous structure and macroporous structure; (III) The first support layer and / or the second support layer are temperature-sensitive support layers, which are used to adjust their water permeability based on temperature changes; (IV) The porosity of the first support layer and / or the second support layer is 5% to 30%; (V) The pore size of the first support layer and / or the second support layer is 5μm~50μm.
9. The lozenge as described in claim 1, characterized in that, The first support layer and the second support layer together form a bag structure, the bag structure having a receiving space, in which the functional layer and the flavoring layer are received.
10. The lozenge as described in claim 1, characterized in that, The mouthpiece further includes a gripping portion connected to the first support layer and / or the second support layer, the gripping portion being used to grip the mouthpiece.